Aztreonam plus clindamycin as therapy for pelvic infections in women.
Aztreonam, a new monobactam antibiotic with specific gram-negative aerobic activity, was used in combination with clindamycin in the treatment of 40 women with pelvic infection, including post-partum endometritis, pelvic inflammatory disease, and post-hysterectomy pelvic cellulitis. Clinical cure was achieved in 87 percent of patients. Failure was related to the limited gram-positive aerobic spectrum of clindamycin. All aerobic gram-negative enteric organisms were sensitive in vitro to less than 0.125 microgram/ml of aztreonam.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001398:Aztreonam; D001424:Bacterial Infections / Q000188:drug therapy*; D002981:Clindamycin / Q000008:administration & dosage*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004716:Endometritis / Q000188:drug therapy; D005260:Female; D006088:Gram-Negative Aerobic Bacteria / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D010249:Parametritis / Q000188:drug therapy; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D002981:Clindamycin; D001398:Aztreonam